Trials / No Longer Available
No Longer AvailableNCT05269771
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
Treatment Plan for Managed Access Program (MAP) to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera (PV)
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 12 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.
Detailed description
The requesting Treating Physician must submit a request for access to drug (often referred to as Compassionate Use) to Novartis which will review and approve by the medical team experienced with the drug and indication.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib | Patients may self-administer daily ruxolitinib tablets qd or bid orally, without regard to food, in accordance with specified dosing schedule provided by the investigator. |
Timeline
- First posted
- 2022-03-08
- Last updated
- 2025-11-05
Locations
25 sites across 8 countries: Australia, Belgium, Canada, Iran, Israel, Netherlands, Poland, United Kingdom
Source: ClinicalTrials.gov record NCT05269771. Inclusion in this directory is not an endorsement.